Dr. Shiva Gopal’s Participation in the New MS Treatment, HDTIT/HCT

Dr. Shiva Gopal Vasishta is an MD specializing in practicing neurology and psychology in Voorhees, New Jersey. He earned a medical degree from the Government Medical College in 1979 and has experience in the field spanning 40 years. Shiva signed up for residency at the Boston City Hospital and Tufts Medical Center, and currently, practices medicine at Eastern Neurodiagnostic Associates and has an affiliation with Kennedy Health System Cherry Hill Campus. Dr. Shiva’s treatment program accepts various insurance plans such as Medicare, Aetna, and Horizon Blue Cross Blue Shield. He actively participates in the Medicare program and regularly accepts Medicare assignments, meaning he takes patients who have an approved Medicare amount.

Dr. Shiva Vasishta serves as a member of the Eastern Neurodiagnostic Association Pc Group and is certified by the board of neurology as a licensed practitioner. As a neurologist, Shiva Gopal treats seizures, epilepsy, dementia, headaches, sleep disorders, stroke, neuromuscular ailments and MS. Some medical professionals do not allow direct billing of Medicare, but Shiva allows payment done through the Eastern Neurodiagnostic Association Pc using his NPI number, PECOS PAC ID and the Enrollment ID. Dr. Shiva Gopal’s license allows him to administer the newly approved treatment, HDIT/HCT. The treatment which has proven to be more efficient for long-term MS ailments eliminates the need to retake MS medications in future and reoccurrence of new MS symptoms, progressive disability, and brain lesions. According to the study, the HDIT/HCT treatment is more effective than all MS medications and therapies.

The study to develop the HDIT/HCT treatment, HALT-MS, was conducted with the sponsorship of the National Institute of Allergy and Infectious Diseases. I began in December 2014 with the financial assist of Immune Tolerance Network and concluded on February 1st, 2017. The researchers documented the study in the medical journal, Neurology, of the American Academy of Neurology. According to Daniel Rotrosen, the director of NIAD’s Branch of Transplantation, Allergy, and Immunology, the new MS treatment will be a revolutionary innovation for the medical world. He stated that patients ailing from relapsing MS and those who do not respond to conventional MS therapies would benefit greatly from the HDIT/HCT.